Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2021-06-01 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "Management's Discussion and Analysis of Financial Condition and Results of Operations for the Quarter Ended March 31, 2021," which is a classic indicator of an MD&A report. It references the interim consolidated financial statements for the quarter ended March 31, 2021, indicating it covers a quarterly period. The content includes detailed discussion of financial condition, results, forward-looking statements, recent developments, and business strategy, which are typical components of an MD&A. The document length is substantial (15,000 characters), and it contains substantive financial and operational analysis rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2021
2021-06-01 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-06-01 English
News release - English.pdf
Regulatory Filings
2021-05-31 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'AGENCY AGREEMENT' and details terms related to the issuance and sale of subscription receipts by iCo Therapeutics Inc. It includes definitions, terms of the offering, escrow conditions, and other contractual provisions. There is no indication that this is a financial report, earnings release, or regulatory filing announcing results or changes. Instead, it is a legal agreement related to capital raising and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the agreement itself, not a brief announcement or certification.
2021-05-14 English
Other.pdf
Merger & Acquisition Classification · 100% confidence The document is titled 'Arrangement Agreement' between two companies, Satellos Bioscience Inc. and ICO Therapeutics Inc., dated March 21, 2021. It contains detailed legal and contractual provisions including definitions, covenants, conditions precedent, representations and warranties, and schedules related to a corporate arrangement. The content focuses on the terms and conditions of a merger or acquisition transaction, including shareholder meetings, court orders, and regulatory approvals. There is no indication that this is a financial report, earnings release, or regulatory filing. Instead, it is a formal agreement documenting the terms of a merger or acquisition. Therefore, the document fits the category of Merger & Acquisition (MA) filings, which include merger communications and agreements.
2021-05-14 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing that a subsidiary of iCo Therapeutics will present research results at a pharmaceutical sciences meeting. It discusses upcoming presentations and research abstracts but does not contain any financial data, regulatory filings, or detailed company reports. It is an announcement related to scientific research presentations rather than a financial or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is more aligned with an Investor Presentation or general company announcement, but since it is a press release about research presentations and not a detailed investor presentation, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2021-05-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.